E-M ADC / Jiangsu Hengrui Pharma - LARVOL DELTA

E-M ADC, a promising EGFR-MUC1 bispecific antibody drug conjugate, with superior anti-tumor effect in a wide range of tumors (AACR 2025) - "Half-life of E-M-TOPi was more than 4 days in cyno monkey. In summary, by fine-tuning the EGFR-MUC1 bispecific antibody affinity and incorporating a superior bystander effect, E-M-TOPi holds the potential to be a best-in-class therapeutic candidate."

Breast Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • MUC1